Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. develops plant-based compounds through its proprietary Botanical Synthesis technology platform, which is designed to grow plant compounds without cultivating the underlying plant. Company news centers on two business verticals: a direct-to-consumer products business built around proprietary nutraceutical health and wellness products, including VINIA, and a CDMO business serving customers seeking novel plant-based compounds.
Recurring updates include financial results, product commercialization, direct-to-consumer growth, CDMO development programs, and applications of the platform in areas such as nutraceuticals and fragrance molecules. BioHarvest also reports governance and leadership changes, equity-based compensation actions, financing activity, and conference participation tied to its public-company profile.
BioHarvest Sciences (BHST) plans a dual listing of its ordinary shares on the Tel Aviv Stock Exchange, alongside Nasdaq, with trading on TASE expected to begin on September 8, 2026.
The company has requested registration on TASE of all 22,667,842 outstanding common shares, up to 4,516,021 shares reserved for its Equity Incentive Plan, and 610,742 shares issuable upon exercise of existing investor warrants. Any future additional share listings will require TASE approval. Shares are expected to trade under the English symbol BHST and an alternative Hebrew symbol, with future EDGAR filings to be concurrently filed via Israel’s MAGNA system.
BioHarvest (NASDAQ: BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, with a gross margin of 58% versus 59% last year. Operating loss was $2.5 million and net loss $3.7 million, while Adjusted EBITDA loss widened to $1.6 million.
The company secured its first CDMO manufacturing and supply agreement with a UAE-based customer to support an anticipated 20-ton production program of a rare, high-value botanical fragrance, with limited output expected from 1H 2027. According to BioHarvest, cash and bank deposits reached $16.25 million as of June 30, 2026.
BioHarvest received a $1.4 million Israel Innovation Authority grant, advanced a $1.125 million saffron program to Stage 2, and expanded its Tate & Lyle sweetener collaboration. The VINIA D2C business grew revenue 2% year-over-year with about 95,000 active customers, but full-year VINIA revenue and EBITDA guidance were reduced as spending is redirected to manufacturing capacity and CDMO investments.
BioHarvest (NASDAQ: BHST) announced an exclusive manufacturing and supply agreement with its existing, undisclosed UAE fragrance partner to produce a rare, endangered fragrance plant cell culture through 2027 and 2028. The deal extends a prior agreement and designates BioHarvest as the exclusive manufacturing partner for the partner’s proprietary cell culture composition.
The company plans to begin limited production in the first half of 2027, with anticipated total volumes of up to 20 metric tons, subject to final product specifications. Contingent on successful delivery, BioHarvest estimates it could recognize $20–$30 million in revenue at completion. The project builds on Stage 1 and Stage 2 R&D milestones reached earlier in the year and leverages BioHarvest’s Botanical Synthesis platform to supply sustainable, consistent rare fragrance molecules. BioHarvest also retains a 20% ownership stake in the developed composition, supporting its entry into the premium fragrance segment, which it cites as a $23 billion part of the $58.9 billion global scents and fragrances market.
BioHarvest Sciences (NASDAQ: BHST) announced that CEO Zaki Rakib will present at the Canaccord Genuity 46th Annual Growth Conference, held August 11-13, 2026, in Boston, Massachusetts. The company presentation is scheduled for Wednesday, August 12, 2026, at 1:00 p.m. ET.
The in-person session will take place in Abigail Adams C at the InterContinental Hotel in Boston, with a publicly accessible live webcast available to online pre-registrants at the provided link. According to BioHarvest, investors can request one-on-one meetings with the company through their Canaccord Genuity representative. The conference connects global institutional investors with growth companies across Technology, Healthcare & Life Sciences, Sustainability, Industrials, and Consumer & Retail sectors.
BioHarvest Sciences (NASDAQ: BHST) announced it will report its second quarter 2026 financial results before market open on Tuesday, August 11, 2026. Management will host a conference call and live webcast at 8:00 AM Eastern Time to review results, business operations, and the 2026 strategy and growth plan.
The webcast can be accessed at https://events.q4inc.com/attendee/553034064, with replay available later in the Investor Relations/Events & Presentations section of the company’s website. Shareholders and investors are invited to join CEO Zaki Rakib and the team for the update.
BioHarvest Sciences (NASDAQ: BHST) received approval from the Israel Innovation Authority for a 4.33 million NIS (about USD $1.4 million) non-dilutive grant to fund an AI-driven plant-cell synthesis R&D program. The zero-interest, milestone-based loan will support integrating data science, machine learning, computer vision and digital sensing into BioHarvest's plant cell culture workflows.
The initiative aims to replace empirical trial-and-error with predictive, data-driven optimization to forecast plant cell propagation and maximize active metabolite yields. This is the second IIA grant BioHarvest has received this year, complementing a prior facility automation grant and together supporting a transformation from AI-powered discovery to autonomous commercial production.
BioHarvest Sciences (NASDAQ: BHST) will present at the 2026 BIO International Convention in San Diego on June 22-25.
The company’s June 24 presentation will highlight its proprietary Botanical Synthesis™ platform for scalable, pharmaceutical-grade plant-derived compounds and its efforts to engage partners across drug discovery, APIs, and next-generation therapeutics.
BioHarvest Sciences (NASDAQ:BHST) expanded its collaboration with Tate & Lyle to develop multiple plant-based sweetener molecules using BioHarvest's Botanical Synthesis™ platform.
The program targets sugar and calorie reduction, sugar-like taste, and responsible sourcing across diverse food and beverage categories, aligned with strong consumer demand for fruit- and plant-derived sweeteners.
BioHarvest Sciences (NASDAQ:BHST) reported Q1 2026 revenue of $8.5 million, up 8% year over year, with a 59% gross margin and net loss of $2.6 million. Full-year revenue guidance remains $42–$48 million.
CDMO revenue grew 135% YoY, supported by Stage 2 contracts worth over $2.2 million for rare fragrance and saffron programs. The VINIA brand reached 90,000 active users, with its Blood Flow Hydration product generating $920,000 in cumulative revenue and 20% of new customer revenue year-to-date.
BioHarvest Sciences (NASDAQ: BHST) appointed Nedira Salzman-Frenkel as Vice President of Business Development for its CDMO division. She will source and manage contracts across pharmaceutical, nutraceutical, nutrition, and cosmetic markets, supporting revenue targets and the planned launch of a new facility next year.
Salzman-Frenkel previously held senior roles in biotech, CRO, and pharma-focused businesses, including securing about $30 million in CRO contracts and leading a binding licensing term sheet with a top global pharmaceutical company for Phase 3 clinical development.